Marion Subklewe

Siemens (Germany) — Germany

Medicine · Health Sciences

58h-index15.7kcitations417works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(234), Immunotherapy and Immune Responses(73), Acute Myeloid Leukemia Research(72), Immune Cell Function and Interaction(62), Lymphoma Diagnosis and Treatment(55)

Publications416 total

Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma
Blood·2025
Correction: Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis
Infection·2025Open Access
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study
Frontiers in Oncology·2025Open Access
TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity
Journal for ImmunoTherapy of Cancer·2025Open Access
Supplementary Figures from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
2025Open Access
Supplementary Tables from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
2025Open Access
Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma
Blood·2025Open Access
Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study
Blood·2025Open Access
P08.11.A MANAGEMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME FOLLOWING CAR-T CELL THERAPY IN CLINICAL PRACTICE: A MULTICENTRIC, RETROSPECTIVE, REAL-WORLD ANALYSIS OF TREATMENT APPROACHES AND OUTCOMES
Neuro-Oncology·2025Open Access
Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis
Infection·2025Open Access
A platform of robust patient-derived leukemia models covering subgroups for which no cell lines exist
2025Open Access
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Blood Cancer Journal·2025· 1 citedOpen Access
Immuntherapie der akuten myeloischen Leukämie - Targets, Plattformen und Perspektiven
Trillium Krebsmedizin·2025
Supplementary Table S7 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
2025Open Access
Supplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
2025Open Access
Supplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
2025Open Access
Supplementary Table S1 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
2025Open Access
Supplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
2025Open Access
Supplementary Table S3 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
2025Open Access
Supplementary Figure S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
2025Open Access
page 1 of 21Next →

Frequent Co-authors

Karsten Spiekermann(14), Klaus H. Metzeler(12), Tobias Herold(9), Wolfgang Hiddemann(9), Christina Krupka(9), Stefan K. Bohlander(7), Thomas Köhnke(7), Sebastian Kobold(6), Maja Rothenberg‐Thurley(6), Stephanie Schneider(6), Wolfgang E. Berdel(6), Jan Braess(6), Felix S. Lichtenegger(6), Ralph M. Steinman(5), Bruno L. Cadilha(5), Stefan Endres(5), Nikola P. Konstandin(5), Bianka Ksienzyk(5), Philipp A. Greif(5), Bernhard Wörmann(5)